US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
WO1988001649A1
(en)
|
1986-09-02 |
1988-03-10 |
Genex Corporation |
Single polypeptide chain binding molecules
|
WO1989008114A1
(en)
|
1988-02-25 |
1989-09-08 |
The General Hospital Corporation |
Rapid immunoselection cloning method
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
KR100206524B1
(ko)
|
1990-07-13 |
1999-07-01 |
어니스트 엠. 해데드 |
씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
DE69233745D1
(de)
|
1991-12-02 |
2008-10-23 |
Cambridge Antibody Tech |
Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
|
CA2150262C
(en)
|
1992-12-04 |
2008-07-08 |
Kaspar-Philipp Holliger |
Multivalent and multispecific binding proteins, their manufacture and use
|
WO1994017184A1
(en)
|
1993-01-29 |
1994-08-04 |
Schering Corporation |
Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
|
GB9424449D0
(en)
|
1994-12-02 |
1995-01-18 |
Wellcome Found |
Antibodies
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
JP4233608B2
(ja)
|
1996-10-15 |
2009-03-04 |
塩野義製薬株式会社 |
自己抗体測定方法
|
CA2269060C
(en)
|
1996-10-17 |
2009-04-07 |
Immunomedics, Inc. |
Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
|
WO2000006194A2
(en)
|
1997-02-05 |
2000-02-10 |
Biotransplant, Inc. |
Depletion of cells responsible for antibody-mediated graft rejection
|
CA2288232A1
(en)
|
1997-05-02 |
1998-11-12 |
The Government Of The United States, Represented By The Secretary, Depar Tment Of Health And Human Services |
Immunotoxins directed against malignant cells
|
JP2003524587A
(ja)
|
1998-06-05 |
2003-08-19 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
多発性骨髄腫を処置するための、cd38に対する、遺伝子操作した抗体の使用
|
US6838283B2
(en)
|
1998-09-29 |
2005-01-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of survivin expression
|
US6335194B1
(en)
|
1998-09-29 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of survivin expression
|
US7223397B1
(en)
|
1999-01-07 |
2007-05-29 |
Research Development Foundation |
Potentiation of anti-CD38-Immunotoxin cytotoxicity
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6608108B2
(en)
|
1999-10-15 |
2003-08-19 |
Johns Hopkins University |
Method for treatment of tumors using nordihydroguaiaretic acid derivatives
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
AU2001232286A1
(en)
|
2000-02-15 |
2001-08-27 |
Yamanouchi Pharmaceutical Co..Ltd. |
Fused imidazolium derivatives
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
JP2003535908A
(ja)
|
2000-06-22 |
2003-12-02 |
アイデック ファーマスーティカルズ コーポレイション |
二重特異性融合タンパク及び標的細胞を殺傷するエフェクター細胞を増強するための使用方法
|
EP1174440A1
(en)
|
2000-07-19 |
2002-01-23 |
U-BISys B.V. |
A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
|
EP1326998A4
(en)
|
2000-10-17 |
2005-05-11 |
Trudeau Inst Inc |
MODIFIED CHEMOTAXIS GENE CD38
|
US20070042436A1
(en)
|
2000-10-17 |
2007-02-22 |
Lund Frances E |
CD38 modulated chemotaxis
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
US20040166490A1
(en)
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
EP1525223B1
(en)
|
2002-06-13 |
2007-11-21 |
Crucell Holland B.V. |
Ox40 (=cd134) receptor agonists and therapeutic use
|
MXPA05009429A
(es)
|
2003-03-05 |
2005-12-12 |
Halozyme Inc |
Glicoproteina hialuronidasa soluble (shasegp), proceso para preparar la misma, usos y composiciones farmaceuticas que la comprenden.
|
US20060223831A1
(en)
|
2003-04-15 |
2006-10-05 |
Isao Kinoyama |
Bromide and its crystal
|
ME00425B
(me)
|
2003-05-30 |
2011-10-10 |
Genentech Inc |
Liječenje sa anti-vegf antitijelima
|
WO2004111233A1
(ja)
|
2003-06-11 |
2004-12-23 |
Chugai Seiyaku Kabushiki Kaisha |
抗体の製造方法
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
EP1689435A4
(en)
|
2003-10-22 |
2007-10-03 |
Univ Rochester |
ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS
|
KR101128777B1
(ko)
|
2003-11-04 |
2012-04-13 |
조마 테크놀로지 리미티드 |
다발성 골수종을 치료하기 위한 길항제 항-cd40단클론성 항체의 용도
|
ATE536376T1
(de)
|
2003-12-23 |
2011-12-15 |
Crucell Holland Bv |
Humanes bindungsmolekül gegen cd1a
|
SG142330A1
(en)
|
2004-02-06 |
2008-05-28 |
Morphosys Ag De |
Anti-cd38 human antibodies and uses therefor
|
CA2555185C
(en)
|
2004-02-06 |
2020-03-24 |
Morphosys Ag |
Anti-cd38 human antibodies and uses therefor
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
US20090123950A1
(en)
|
2005-05-24 |
2009-05-14 |
Morphosys Ag |
Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
|
ME02886B
(me)
|
2005-10-12 |
2018-04-20 |
Morphosys Ag |
Proizvodnja i karakterizacija potpuno humanih terapeutskih antitela dobijenih HuCAL GOLD tehnologijom, specifičnih za humani CD38
|
AU2006329944A1
(en)
|
2005-12-09 |
2007-07-05 |
Seattle Genetics, Inc. |
Methods of using CD40 binding agents
|
CA2646965C
(en)
|
2006-03-24 |
2016-06-21 |
Jonathan H. Davis |
Engineered heterodimeric protein domains
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
CA2659861A1
(en)
|
2006-08-02 |
2008-02-07 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
|
WO2008073160A2
(en)
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
NZ576122A
(en)
|
2006-09-26 |
2012-09-28 |
Genmab As |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
US7618992B2
(en)
|
2006-12-29 |
2009-11-17 |
Astellas Pharma Inc. |
Method of treating cancer by co-administration of anticancer agents
|
MX2009010282A
(es)
|
2007-03-29 |
2009-10-12 |
Genmab As |
Anticuerpos biespecificos y metodos para su produccion.
|
US20100330081A1
(en)
|
2007-06-01 |
2010-12-30 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
US20090076249A1
(en)
|
2007-09-19 |
2009-03-19 |
Michel De Weers |
Antibodies against CD38 for treatment of multiple myeloma
|
WO2009044793A1
(ja)
|
2007-10-02 |
2009-04-09 |
Alphagen Co., Ltd. |
癌遺伝子を標的とするsiRNA
|
WO2009062054A1
(en)
|
2007-11-09 |
2009-05-14 |
Novartis Ag |
Uses of anti-cd40 antibodies
|
US8440199B2
(en)
|
2007-12-12 |
2013-05-14 |
Imperial Innovations Limited |
Methods for mobilizing mesenchymal stem cells in a patient
|
JP2011507519A
(ja)
|
2007-12-19 |
2011-03-10 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
|
PL2235064T3
(pl)
|
2008-01-07 |
2016-06-30 |
Amgen Inc |
Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
|
JP2011517320A
(ja)
|
2008-03-03 |
2011-06-02 |
ダイアックス コーポレーション |
メタロプロテアーゼ9結合タンパク質およびメタロプロテアーゼ2結合タンパク質
|
WO2009114476A1
(en)
|
2008-03-12 |
2009-09-17 |
Intradigm Corporation |
Compositions comprising survivin sirna and methods of use thereof
|
CL2009000713A1
(es)
|
2008-03-25 |
2010-04-09 |
Hoffmann La Roche |
Composicion farmaceutica que comprende un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada y uno o mas agentes quimioterapeuticos; y su uso para tratar un cancer que expresa cd20.
|
KR20100135291A
(ko)
|
2008-04-14 |
2010-12-24 |
할로자임, 아이엔씨 |
히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
CN107184977A
(zh)
|
2008-11-07 |
2017-09-22 |
安进研发(慕尼黑)股份有限公司 |
急性淋巴细胞白血病的治疗方法
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
US8710068B2
(en)
|
2009-01-19 |
2014-04-29 |
The Trustees Of The University Of Pennsylvania |
Method of treating cancer using a survivin inhibitor
|
WO2010129304A2
(en)
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
PL2429524T3
(pl)
|
2009-05-14 |
2020-08-24 |
Ambit Biosciences Corporation |
Suszony rozpyłowo preparat AC220
|
US9345661B2
(en)
*
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
US9084743B2
(en)
|
2009-09-17 |
2015-07-21 |
Baxter International Inc. |
Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
US20130137134A1
(en)
|
2010-03-29 |
2013-05-30 |
Ben Gurion University Of The Negev Research And Development Authority |
Method and system for detecting and monitoring hematological cancer
|
CN103097417B
(zh)
|
2010-04-20 |
2019-04-09 |
根马布股份公司 |
含异二聚体抗体fc的蛋白及其制备方法
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
JP6093696B2
(ja)
|
2010-06-09 |
2017-03-08 |
ゲンマブ エー/エス |
ヒトcd38に対する抗体
|
EP2420253A1
(en)
|
2010-08-20 |
2012-02-22 |
Leadartis, S.L. |
Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
|
ES2617446T3
(es)
|
2010-09-27 |
2017-06-19 |
Morphosys Ag |
Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
KR20190120439A
(ko)
*
|
2010-11-08 |
2019-10-23 |
제넨테크, 인크. |
피하 투여용 항―il―6 수용체 항체
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
CL2013001944A1
(es)
|
2010-12-30 |
2014-09-12 |
Takeda Pharmaceutical |
Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.
|
DK2937349T3
(en)
|
2011-03-23 |
2017-02-20 |
Amgen Inc |
CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
|
EP2561868A1
(en)
|
2011-08-24 |
2013-02-27 |
Anton Bernhard Van Oosten |
Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
|
CN109022465B
(zh)
|
2011-10-28 |
2022-04-29 |
特瓦制药澳大利亚私人有限公司 |
多肽构建体及其用途
|
AU2013243873B2
(en)
|
2012-04-04 |
2016-08-25 |
Halozyme, Inc. |
Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
|
SG11201407190TA
(en)
|
2012-05-15 |
2014-12-30 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
US9579378B2
(en)
|
2012-09-25 |
2017-02-28 |
Morphosys Ag |
Combinations and uses thereof
|
US9486547B2
(en)
|
2012-11-05 |
2016-11-08 |
Morphosys Ag |
Radiolabelled antibody and uses thereof
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
WO2014142220A1
(ja)
|
2013-03-13 |
2014-09-18 |
アステラス製薬株式会社 |
抗腫瘍剤
|
US20140271644A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Combination/adjuvant therapy for wt-1-positive disease
|
UA113129C2
(xx)
|
2013-04-29 |
2016-12-12 |
|
ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b
|
US20140356318A1
(en)
|
2013-05-28 |
2014-12-04 |
Israel Barken |
Adoptive cell therapy with specific regulatory lymphocytes
|
CN105579058A
(zh)
|
2013-07-15 |
2016-05-11 |
小利兰·斯坦福大学托管委员会 |
Cd38激动剂的医学用途
|
TN2016000142A1
(en)
|
2013-10-31 |
2017-10-06 |
Sanofi Sa |
Specific anti-cd38 antibodies for treating human cancers.
|
JP2016536361A
(ja)
|
2013-11-06 |
2016-11-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd33抗体及び脱メチル剤を含む医薬配合物
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
WO2015195555A1
(en)
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
|
EP3154581B1
(en)
|
2014-06-16 |
2019-02-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
MX2017003115A
(es)
|
2014-09-09 |
2017-11-17 |
Janssen Biotech Inc |
Terapias de combinacion con anticuerpos anti-cd38.
|
CN107406506A
(zh)
|
2014-12-04 |
2017-11-28 |
詹森生物科技公司 |
用于治疗急性髓系白血病的抗cd38抗体
|
JP6827426B2
(ja)
|
2015-05-20 |
2021-02-10 |
ヤンセン バイオテツク,インコーポレーテツド |
軽鎖アミロイドーシス及びその他のcd38陽性血液悪性疾患の治療のための抗cd38抗体
|
AU2016282674B2
(en)
|
2015-06-22 |
2022-01-13 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
DK3313441T3
(da)
|
2015-06-24 |
2024-04-15 |
Janssen Biotech Inc |
Immunmodulering og behandling af faste tumorer med antistoffer, der specifikt binder cd38
|
US20170121417A1
(en)
|
2015-11-03 |
2017-05-04 |
Janssen Biotech, Inc. |
Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
|
LT3827845T
(lt)
|
2015-11-03 |
2022-06-10 |
Janssen Biotech, Inc. |
Poodinės anti-cd38 antikūnų kompozicijos ir jų naudojimas
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
WO2018002181A1
(en)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
|
US20180117150A1
(en)
|
2016-11-01 |
2018-05-03 |
Janssen Biotech, Inc. |
Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
|
US11618787B2
(en)
|
2017-10-31 |
2023-04-04 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|